The German pulmonary hypertension association ph e.v. has published the August edition of its magazine “Rundbrief”, very rich in content as always. Key topics covered include: Research and Medical Advances: Clinical Practice: Professional Development: PDF In German available here
Risk scores designed for pulmonary arterial hypertension (Group I of the World Health Organisation classification for pulmonary hypertension) do not adequately account for the unique pathophysiology seen in patients whose pulmonary hypertension arises from underlying lung disease (Group III of the World Health Organisation (WHO) classification). This is the rationale behind a retrospective study of
Anna Jeter, is an artist, writer and photographer living in Excelsior, Minnesota, USA. She was diagnosed with pulmonary arterial hypertension at the age of 4 but only received a heart-lung transplant 19 years later, in 2018. In a recent article for Pulmonary Hypertension News she expresses gratitude for surviving long enough to receive the transplant
Terumo, a leading medical technology company based in Japan, has announced a definitive agreement to acquire all outstanding shares of OrganOx, for approximately $1.5 billion. OrganOx specializes in advanced organ preservation devices using Normothermic Machine Perfusion technology, which preserves organs longer by circulating oxygen and nutrient-rich fluids through organs at near-body temperature. This technology enables
Members and supporters of the Pulmonary Vascular Research Institute (PVRI) are taking on a global challenge to raise awareness for pulmonary hypertension (PH). So far, 24 participants have pledged a combined 3,901 km (2,438 miles) — enough to travel from Athens to Dublin, crossing 12 countries! Why Dublin? The virtual “arrival” in Dublin is particularly
This global study spanning from 1990 to 2021, published in Pulmonary Circulation, aimed to delineate the global burden of pulmonary arterial hypertension among women of childbearing age. The research reveals both encouraging and concerning trends. While mortality and disability rates have declined over the past three decades due to improved treatments, the absolute number of
An article titled “The Genesis and Legacy of the NHLBI Patient Registry for the Characterization of Primary Pulmonary Hypertension”, published recently in Pulmonary Circulation, traces the historical development of primary pulmonary hypertension (PPH) research from its first pathological description by Ernest Romberg in 1891 through the establishment of the landmark US National Heart, Lung, and
Cereno Scientific announced on August 26, 2025 that the US Food and Drug Administration (FDA) has granted Fast Track designation to CS1, its lead drug candidate for treating pulmonary arterial hypertension (PAH). This designation accelerates development and regulatory review for treatments addressing serious conditions with high unmet medical need. In a Phase IIa trial, it
On Wednesday October 1, 2025, a special programme at the European Respiratory Congress will be discussing what can ERN-LUNG offer for the future. ERN-LUNG is a patient-centric network of European healthcare providers and patient organisations, committed Europe-wide and globally to reducing morbidity and mortality from rare lung diseases in people of all ages through: ✅
On BBC News on 22 August 2025, Emma Stanley tells the incredible story of Catherine Makin, a double lung transplant patient. Catherine Makin, 42, a National Health Service (NHS) clerical worker from Great Harwood, Lancashire, has won 10 medals in swimming and table tennis at the British Transplant Games after receiving a double lung transplant
Previous studies have shown that pulmonary arterial hypertension patients have different gut bacteria compositions, with lower diversity and fewer anti-inflammatory bacteria that produce beneficial short-chain fatty acids. Could the gut-lung connection contribute to pulmonary arterial hypertension development through enhanced nerve communication and altered bacterial metabolites like trimethylamine-N-oxide? In this two-sample Mendelian randomization study, recently published
Despite strong recommendations to assess quality of life in pulmonary arterial hypertension patients from the World Symposia on Pulmonary Hypertension (WSPH) in 2018 and 2024, and from the 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) joint pulmonary hypertension guidelines, this evaluation remains rarely implemented in clinical practice. This cross-sectional study of
A study recently published on BMC Pulmonary Medicine compared baseline characteristics and short-term efficacy of pulmonary endarterectomy (gold standard for operable chronic thromboembolic pulmonary hypertension, removing thickened intima and organized thrombus from pulmonary arteries) vs. balloon pulmonary angioplasty (an option for inoperable chronic thromboembolic pulmonary hypertension, improving blood flow by dilating stenosed/occluded vessels without removing lesions), particularly
The Research: Evidence on the predictive ability of risk assessment models for event-free survival (EFS) in patients with pulmonary arterial hypertension is scarce, say the authors of a recent study published on Pulmonary Circulation. The aim of the study was to evaluate how well three different risk assessment models predict event-free survival. The study included 411
Current targeted medications for pulmonary arterial hypertension can help symptoms but have limited long-term effectiveness and often cause significant side effects and high costs. Percutaneous pulmonary artery denervation is a realtively new interventional procedure that selectively destroys sympathetic nerves to restore nerve and hormone balance in patients who don’t respond well to standard medications – see
In episode 530 of the phaware® podcast Drs. Victor Test, Deborah Levine and Rodolfo Estrada discuss CHEST’s First 5 Minutes® program, which helps medical professionals build the skills that lead to a positive relationship with patients from the get-go, creating trust and developing empathy to build rapid rapport and communicate with patients. The goal is to
“First five minutes”: building patient trust, a PHAWARE GLOBAL podcast, July 22, 2025 Read Post »
People with interstitial lung disease (ILD), such as idiopathic pulmonary fibrosis (IPF), cansometimes also develop pulmonary hypertension – high blood pressure in the lungs.Unfortunately, there are no approved medicines for pulmonary hypertension in interstitial lung disease, and survival can be poor, especially in severe cases. A large international study titled “Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment
A recent study titled “Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes” analysed two common health factors in people with pulmonary hypertension: inflammation and body weight. Inflammation is associated with all types of pulmonary hypertension. In the study inflammation was measured by a blood test called C-reactive protein (CRP), and body
Award-winning singer-songwriter Chloe Temtchine has released a new single “Heaven in the Darkest Place” featuring rapper Freeway. The song is inspired by Temtchine’s own near-death experience and life-saving double-lung transplant. Key collaborator: Freeway brings personal significance to the track – he received a kidney transplant in 2019. Broader purpose: The song serves as the official
INTRODUCTION Ever wondered how we went from completely misunderstanding blood flow for 1,400 years to performing open-heart surgery? A fascinating historical review by Prof. Adam Torbicki, published in Diagnostics (2021), reminds us that while most modern clinicians “look forward, expecting new pathophysiological pathways to be explored,” few take time “to look into the past.” Yet
